Results 121 to 130 of about 24,764 (229)

Proarrhythmia associated with antiarrhythmic drugs: a comprehensive disproportionality analysis of the FDA adverse event reporting system. [PDF]

Front Pharmacol, 2023
Wang F, Zhou B, Sun H, Wu X.
europepmc   +1 more source

Catheter ablation vs antiarrhythmic drugs for persistent atrial fibrillation in hypertrophic cardiomyopathy. [PDF]

Heart Rhythm O2
Shahrori Z, Rayyan A, Sharma S, Sallam L, Arruda M, Mackall J, Sharma E.   +6 more
europepmc   +1 more source

Predictors and Outcomes of 30‐Day Readmissions Following Electrical Cardioversion for Atrial Fibrillation: Insights From the Nationwide Readmissions Database

Journal of Arrhythmia, Volume 42, Issue 4, August 2026.
Among 134 114 atrial fibrillation hospitalizations treated with electrical cardioversion in the 2016–2017 NRD, 9.9% resulted in 30‐day readmission. Readmission was associated with higher mortality, longer stay and greater costs. Predictors included cardiometabolic comorbidities, female sex, lower income, Medicare/Medicaid insurance, nonhome discharge ...
Adeena Jamil, Muhammad Umer Sohail, Asad Ali Ahmed Cheema, Syed Usama Ashraf, Anushah Faheem Ilyas, Faizan Abbas, Shaikh Jehanzaib Saeed, Mohammad Rayyan Faisal, Ahmad Murtaza Anwar, Shanzey Rai, Syeda Unzila Tirmizi, Muhammad Uzair, Tooba Shahzad   +12 more
wiley   +1 more source

Comparative effectiveness and safety of oral anticoagulants in patients with atrial fibrillation using antiarrhythmic drugs: An international cohort study. [PDF]

Br J Clin Pharmacol
Meinert FM, Dimakos J, Cui Y, Filion KB, Renoux C, Douros A.   +5 more
europepmc   +1 more source

Blanking period antiarrhythmic drugs after catheter ablation for atrial fibrillation: a meta-analysis of randomized controlled trials. [PDF]

Front Cardiovasc Med, 2023
Chen G, Li G, Zhang D, Wang X, Guo X.
europepmc   +1 more source

Documented Obstructive Sleep Apnea, Cardiometabolic Phenotype, and Rhythm‐Related Outcomes After Atrial Fibrillation Ablation: An Observational Cohort Study

Journal of Arrhythmia, Volume 42, Issue 4, August 2026.
Documented OSAS identified a higher‐risk cardiometabolic phenotype in patients undergoing AF ablation, including greater obesity, hypertension, diabetes, persistent AF, and adverse lipid markers. However, it did not independently predict post‐ablation rhythm‐related outcomes in either the registry cohort or the actively followed cohort.
Yazan Mohsen, Iryna Novikov, Shreeram Sabareesan, Kensuke Sakata, Moritz Knitter, Henning Horlitz, Lucas Steffens, Marc Horlitz, Ibrahim Antoun, Florian Stöckigt   +9 more
wiley   +1 more source

Effectiveness and safety of concomitant use of direct oral anticoagulants and antiarrhythmic drugs: a systematic review of observational studies. [PDF]

Eur J Clin Pharmacol
Meinert FM, Dimakos J, Riemer TG, Douros A.   +3 more
europepmc   +1 more source

Effects of Antiarrhythmic Drugs on Antiepileptic Drug Action-A Critical Review of Experimental Findings. [PDF]

Int J Mol Sci, 2022
Borowicz-Reutt KK.
europepmc   +1 more source

Drug Critical Limits for Urgent Physician Notification

Clinical Pharmacology &Therapeutics, Volume 120, Issue 1, Page 178-192, July 2026.
Critical limits represent quantitative decision thresholds for drugs that require immediate clinician notification and potential life‐saving intervention. United States hospitals lack a national standard for drug critical limits. We collected critical limits from 417 US hospitals across all 50 states and Washington, D.C.; of these, 411 maintained drug ...
Elina Kuang, Yasmeen Ibrahim, Kyle Cheng, Gerald J. Kost   +3 more
wiley   +1 more source

Sacubitril Does Not Exert Proarrhythmic Effects in Combination with Different Antiarrhythmic Drugs. [PDF]

Pharmaceuticals (Basel)
Ellermann C, Mengel C, Wolfes J, Wegner FK, Rath B, Köbe J, Eckardt L, Frommeyer G.   +7 more
europepmc   +1 more source